Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 5 institutions in 2 countries.
Elisa ten HackenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-1573-8799
Shanye YinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9116-5238
Robert ReddDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-1329-5288
María Hernández SánchezThe Institute of Cancer Molecular and Cellular Biology-Cancer Research Center, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain.ORCID 0000-0001-9968-2782
Kendell ClementCenter for Cancer Research, and Center for Computational and Integrative Biology, Molecular Pathology Unit, Massachussetts General Hospital, Boston, MA.ORCID 0000-0003-3808-0811
Gabriela Brunsting HoffmannDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7758-898X
Fara F RegisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Elizabeth WittenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Shuqiang LiTranslational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA.
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Luca PinelloCenter for Cancer Research, and Center for Computational and Integrative Biology, Molecular Pathology Unit, Massachussetts General Hospital, Boston, MA.
Kenneth J LivakTranslational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9105-5856
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3348-5054
Dana-Farber Cancer Institute · USBroad Institute · USCenter for Cancer Research · USHarvard University · USUniversidad Complutense de Madrid · ES
Funding
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI DAVIDS, MATTHEW S · 2016 to 2025
$17.0M
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5M
Multiscale exploration of the functional non-coding genomeR35HG010717 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI PINELLO, LUCA · 2019 to 2023
$2.6M
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4M
Defining the impact of mutational drivers on the immune microenvironment of CLLR21CA267527 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING, YIN, SHANYE · 2022 to 2023
$454k
Pan-disease characterization of DNA methylation dysregulationK99HG011658 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI CLEMENT, KENDELL · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. · full record | OpenQuestion